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Abstract  
Aims: To study the expression of integrins αvβ3 and αvβ5, and their ligands in tumour, 
stroma and endothelial cells from human glioblastoma and CNS metastases from 
breast, lung and skin tumours. 
Methods and results: Integrin and integrin ligand expression was quantified in frozen 
tumour surgical specimens (each 15 glioblastomas and breast carcinoma metastases as 
well as each 16 lung carcinoma and melanoma metastases) using 
immunohistochemistry. Gene expression profiles were evaluated in glioblastomas 
(n=424) and in normal brain (n=11). Overall, αvβ3 expression was more common than 
αvβ5, except in tumours derived from lung. αvβ3 expression was most frequent in 
glioblastomas and melanoma metastases. Most lung-derived tumours expressed αvβ5, 
but expression was less frequent in other tumours; about 20% of breast-derived tumours 
strongly expressed αvβ5. Melanoma-derived tumours did not express αvβ5. Expression 
of integrin ligands vitronectin, fibrinogen, fibronectin and osteopontin was variable 
between tumours, although most tumours expressed the ligands to some extent. Marked 
αvβ3, but not αvβ5, expression was common in stroma of CNS metastases. In blood 
vessels, αvβ3 expression was more frequent than αvβ5 and more pronounced in CNS 
metastases than in glioblastomas. Integrin ligand expression occurred in blood vessels 
in most tumours. In glioblastomas, mRNA expression of αvβ3, αvβ5, osteopontin and 
fibronectin were significantly upregulated over normal brain.  
Conclusions: Overall, we report disinct and heterogenous patterns of integrin 
expression in primary and secondary brain tumours that may be relevant to the future 
development of integrin-targeting therapeutic approaches to brain tumours. 
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Introduction 
Integrins are important in promoting tumour development and metastasis. The 
interaction of integrins with the extracellular matrix influences the assembly and 
organisation of the intracellular cytoskeleton, enhances cell survival and reduces the 
likelihood of apoptosis in a variety of tumour types (Janes and Watt, 2006; Le Tourneau 
et al., 2007; Moschos et al., 2007; Streuli, 2009). The centres of growing solid tumours 
can become hypoxic, which prompts the generation of new blood supply for the tumour 
through angiogenesis, in which integrins expressed by the growing endothelia influence 
migration to and entry into the tumour (Nikolopoulos et al., 2004; Varner and Cheresh, 
1996) .  
Activation of integrins αvβ3 and αvβ5 has been implicated in these cellular 
processes (Enns et al., 2005; Hodivala-Dike, 2008; Beauvais et al., 2009; Somanath et 
al., 2009). In mice with tumours derived from intracranially injected glioblastoma cells, 
the tumours had lower vessel density in αvβ3-deficient (knockout) than in wild-type mice 
(Kanamori et al., 2006). Similarly, inhibition of integrins, including αvβ3, inhibited tumour 
growth in a nude rat model (Mikkelsen et al., 2009). Conversely, increased activation of 
αvβ3 increased the ability of cultured cells to migrate (Verbisck et al., 2009). A further 
experimental study showed that selective inhibition of αvβ3 and αvβ5 integrins with an 
Arg-Gly-Asp (RGD) peptide induced endothelial cell death via anoikis (cell death 
associated specifically with detachment from the extracellular matrix) (Maubant et al., 
2006). In human glioblastoma, the expression of αvβ3 appears to be higher in higher-
grade tumours (glioblastomas World Health Organization [WHO] grade IV relative to 
low-grade astrocytomas), but integrin inhibition induces only detachment, but not anoikis 
(Schnell et al., 2008; Maurer et al., 2009). As the growth of a tumour is influenced 
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strongly by its environment (Kanamori et al., 2006), mechanisms related to the 
expression of αvβ3 and αvβ5 are likely to be relevant to both primary central nervous 
system (CNS) tumours and metastases from other tumour types. Here we have studied 
the expression profile of αvβ3 and αvβ5 and their principal ligands (vitronectin, 
fibrinogen, fibronectin, osteopontin) in primary human CNS neoplasms (WHO grade IV 
glioblastomas) and secondary neoplasms in the brain originating from primary tumours 
in the lung, breast and skin (melanoma) to elucidate potential differences in the 
expression profile of primary and secondary malignant CNS neoplasms. The expression 
pattern of these proteins was studied in tumour parenchyma, stromal cells, and in blood 
vessels. Gene expression profiles of the integrins and their ligands derived from open-
source databases were also evaluated in brain tumours and compared with their 
expression in normal CNS tissues.  
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Materials and Methods 
mRNA expression of integrins and integrin ligands in primary tumour tissues and 
normal tissues 
Differences in the gene expression profile in primary glioblastomas (n=424) versus 
normal CNS tissues (n=11) were assessed from two publicly available platforms at the 
US National Institute of Health: The Cancer Genome Atlas (TCGA) Data Portal 
(http://tcga-data.nci.nih.gov/tcga/tcgaHome2.jsp) and the REpository for Molecular 
BRAin Neoplasia DaTa (REMBRANDT) (https://caintegrator.nci.nih.gov/rembrandt/). 
Both platforms contain clinical information, genomic characterisation data, and high-
throughput sequencing analysis of tumour genomes and provide researchers with the 
ability to perform ad hoc querying across multiple data domains. Since for secondary 
brain tumours (breast and lung) only z-scores, but no expression ratios (mRNA 
expression vs normal tissue), were available, these data were not included in the 
present study. 
 
Preparation of tumour samples and immunohistochemical staining 
Tumour tissue samples were immediately frozen in liquid nitrogen ((each 15 
glioblastomas and breast carcinoma metastases as well as each 16 lung carcinoma and 
melanoma metastases)). Tumour diagnoses were confirmed by at least two 
neuropathologists. Sections of 10 µm thickness were cut using a microtome and 
mounted on Super Frost Plus slides (Microm International, Walldorf, Germany). Sections 
were dried, and postfixed for 10 min in ethanol at 4°C, followed by acetone for 1 min and 
Tris-buffered saline for 5 min at room temperature. For automatic immunohistochemical 
tissue labelling, the Benchmark immunohistochemistry system (Ventana, Strasbourg, 
Michel Mittelbronn   5.7.12 16:11
Michel Mittelbronn   5.7.12 13:08
Michel Mittelbronn   5.7.12 13:09
Michel Mittelbronn   5.7.12 13:08
Gelöscht: cDNA 
Gelöscht: N = 73
Gelöscht: 
Gelöscht:  
6 
 
France) was used. Endogenous peroxidase of the tissue sections was blocked with 3% 
H2O2 in methanol for 14 min. A cell-conditioning pretreatment was performed. Primary 
antibodies (Table 1) were applied at a working concentration of 10 µg ml−1 for 30 min. 
An avidin and a biotin blocker were applied to the samples for 4 min, respectively, 
followed by an 8-min incubation with one drop of I-View-Biotin Ig (Ventana). For 
diaminobenzidine (DAB) visualisation, the sections were incubated with one drop of I-
View streptavidin–horseradish peroxidase for 8 min and then with DAB/H2O2 for an 
additional 8 min. Sections were finally incubated with a copper enhancer (Ventana) for 4 
min, then washed, counterstained with haematoxylin and mounted. Negative and 
isotype controls were conducted for all tumours. 
 
Quantification of expression in tissue sections 
For all tumours, only sections where staining could be unequivocally attributed to blood 
vessels, tumour cells, or stromal cells were evaluated. In CNS metastases, stromal cells 
were defined as non-neoplastic tissue intermingled between tumor cell clusters, blood 
vessels and/or CNS tissue. Astrocytic tumours do not develop stroma, and consist of 
diffusely infiltrating tumour cells which invade preexisting CNS parenchyma, thus, 
expression on stromal cells could not be assessed in these tumours. M. Mittelbronn and 
D. Capper quantified staining intensity and frequency separately for blood vessels, 
tumour and stromal cells (see above), using an Olympus BX50 microscope. Staining 
frequency for tumour and stromal cells was categorised as: 0, no staining; 1, single cells 
positive (focal pattern); 2, single cells positive (diffuse pattern); 3, up to 20% positive 
cells; 4, 20–50% positive cells; or 5, >50% positive cells. Staining frequency for blood 
vessels was categorised as: 0, all vessels negative; 1, moderate number of positive 
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blood vessels; or 2, most blood vessels positive. Staining intensity was categorised as: 
1, weak; 2, moderate; or 3, strong. Statistical analysis was performed by a contingency 
table analysis using χ2 tests. 
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Results 
Expression of αvβ3 and αvβ5 integrins in tumor cells of primary and secondary 
CNS tumours 
Figure 1 summarises the expression of αvβ3 and αvβ5 integrins in tumor cells of primary 
and secondary CNS tumours and Figure 2 shows representative immunohistochemical 
stainings. αvβ3 was more commonly expressed than αvβ5 in tumour cells, except for 
lung carcinomas, in which the tumor cells showed a slightly higher expression frequency 
for αvβ5 than for αvβ3. Glioblastomas and melanoma-derived brain metastases were 
most likely to express αvβ3 in a moderate or high proportion of tumor cells (20-50% or 
>50%). Although, αvβ3 expression was detected in most tumour samples, about one-
third of lung- and breast-derived brain metastases had no αvβ3 expression. The 
intensity of staining in all samples expressing αvβ3 was generally weak (score 1, data 
not shown). In contrast, six out of seven lung-derived brain tumours showed αvβ5-
expressing tumor cells. Expression of this integrin was less frequent in the other tumour 
types: there was no expression of αvβ5 in melanoma-derived and most glioblastomas or 
breast-derived brain metastases did also not express αvβ5. Nevertheless, approximately 
20% of breast-derived brain tumours strongly expressed αvβ5. In general, in 
glioblastomas, integrin αvβ3 was much more strongly expressed as compared to αvβ5. 
Expression intensity of αvβ3 was generally weak in secondary brain tumours, with only 
one sample scoring higher than 1 (a single breast carcinoma which scored 2 
[moderate]). 
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Expression of integrin ligands in tumor cells of primary and secondary CNS 
tumours 
The frequency of expression of integrin ligands is summarised in Figure 3 and 
representative immunohistochemical stainings are shown in Figure 4. About half of the 
glioblastomas and breast-derived brain metastases expressed fibrinogen, although the 
frequency of expression was mostly in <50% of cells. Stronger expression of fibrinogen 
was observed in tumor cells derived from melanoma or especially lung carcinoma 
metastases. Staining intensities for fibronectin in tumor cells were mostly weak, with 
moderate staining intensity observed only in a single glioblastoma sample and in two 
lung-derived tumours. Between one-third and two-thirds of samples from each tumour 
type did not express fibronectin, and no primary or secondary CNS neoplasm expressed 
fibronectin in >50% of all tumor cells. Vitronectin was moderately or strongly expressed 
in all secondary brain tumours studied. In contrast, in glioblastoma, most samples did 
not show a reproducible staining result so that these stainings were not included in the 
evaluation. Osteopontin was expressed by tumor cells of most glioblastomas and the 
majority of lung- and melanoma-derived tumours, whereas expression of this ligand was 
uncommon in breast-derived brain tumours. Intensity scores for osteopontin in 
glioblastoma cells were mostly moderate (9/14), with four samples demonstrating weak 
and one sample strong intensity.  
 
Expression of αvβ3 and αvβ5 integrins and their ligands in stromal cells of 
secondary CNS neoplasms 
Intrinsic brain malignancies do not usually develop stromal elements, so analysis of 
stromal expression was restricted to metastatic brain tumours (Table 3). Marked 
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expression of αvβ3 was observed in tumor-associated stromal cells of the majority of 
lung- and melanoma-derived tumours, and in 40% of breast tumours. αvβ5 expression 
was uncommon in breast tumour stroma and was not studied in lung- or melanoma-
derived tumours since the stromal cells were not unequivocally assessable for αvβ5 in 
these samples. The majority of the metastatic brain tumours showed marked stromal 
expression of fibrinogen, vitronectin and fibronectin (Table 3). In contrast, strong 
expression of osteopontin was only seen in single cases. 
 
Expression of αvβ3 and αvβ5 integrins and their ligands on blood vessels of 
primary and secondary CNS neoplasms 
Most tissue specimens of breast-, lung- and melanoma derived tumours showed 
expression of αvβ3 in most tumor-associated blood vessels, whereas only a minority of 
glioblastoma-associated vessels expressed αvβ3. αvβ5 in blood vessels was generally 
absent or only moderately frequent in both primary and secondary CNS neoplasms. 
Most tumours expressed the integrin ligands in blood vessels at moderate or high 
frequency (Table 4). 
 
mRNA expression of integrins and integrin ligands in glioblastomas compared to 
normal CNS tissues 
Figure 5 illustrates integrin and integrin ligand mRNA expression in glioblastomas 
relative to the normal CNS tissues. cDNA expression of αvβ3 and αvβ5 was significantly 
upregulated in glioblastomas (n = 424) as compared to normal brain (n = 11) (P = 
0.0003 and P = 0.0072, respectively). Regarding the expression of integrin ligands, 
osteopontin demonstrated the strongest upregulation compared with normal brain tissue 
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(P < 0.0001). Fibronectin was also significantly upregulated (P < 0.0001), whereas 
vitronectin and fibrinogen expression in glioblastomas did not significantly differ from 
those in normal brain tissue. 
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Discussion 
We have studied the expression of αv integrins and their ligands in primary and 
metastatic tumours in human brain specimens. Our primary findings are that integrin 
αvβ3 was expressed by most glioblastomas and in brain metastases from breast and 
lung cancers and melanomas, often at high frequencies. Integrin αvβ5 was expressed at 
low frequency in all tumours except in those from lung, where expression frequency was 
higher than that for αvβ3. Our data from glioblastoma samples show that glioblastomas 
express αvβ3 and αvβ5 integrins, both on neoplastic astrocytes and on invasive blood 
vessels (Gladson and Cheresh, 1991; Paulus et al., 1993; Gladson, 1996; Bello et al., 
2001; Kanamori et al., 2004). In contrast to the constantly high αvβ3 expression on 
blood vessels in CNS metastases, αvβ3 expression was considerably lower in primary 
CNS glioblastomas. In contrast to CNS metastases, glioma vascularisation is provided in 
a cooptive manner for a long time (Fischer et al., 2005). In CNS metastases, activated 
blood vessels have to invade actively the cohesive tumor cels clusters. Glioma cells 
often migrate along preexisting blood vessels thereby gaining access to oxygen and 
nutrients. This might be at least partly responsible for a later and more moderate 
activation of glioma-associated blood vessels in contrast to a generally stronger 
expression of integrins in blood vessels associated with CNS metastases. Potentially, 
αvβ3 is just turned on in a distinct temporo-regional manner in case of insufficient supply 
by vascular cooption. In general, our data on integrin expression in secondary brain 
tumours are consistent with reports of αvβ3 and αvβ5 expression in primary breast 
cancer (Meyer et al., 1998; Silvestri et al., 2002; Havaki et al., 2007; Vellon et al., 2007; 
Beer et al., 2008), lung cancer (Chen et al., 2005; Cui et al., 2007; Fong et al., 2009), 
and melanoma (Neto et al., 2007; Tzukert et al,. 2010), where the expression of αvβ3 
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was suggested to be linked to the invasive potential of the tumour cells. Our study also 
defines the expression patterns of αvβ3 and αvβ5 in tumour stroma and endothelial cells 
within the different tumour types. Results in breast- and lung-derived brain metastases 
are consistent with earlier reports of αvβ3 expression in capillaries of primary breast and 
lung carcinomas (Max et al., 1997). 
Expression of integrin ligands was variable in tumour tissues. For all secondary 
brain tumours, vitronectin was the most commonly expressed integrin ligand evaluated. 
The abundant expression of this ligand has been previously reported in primary breast 
cancer (Aaboe et al., 2003); however, to our knowledge, not in the other tumours we 
describe here. The strong expression of vitronectin is all the more of interest since 
emerging evidence especially presents the vitronectin/αvβ3 axis as an important 
pathway affecting intracellular signalling in cancer progression (Reuning, 2011). αvβ3 
was found in more than 50% of all tumor entities at least to some extent in our cohort 
while αvβ3 was absent in all melanomas and approximately 70% of breast carcinomas. 
These findings suggest that especially the inhibition of the vitronectin/αvβ3 pathway 
could be a promising target for secondary brain tumors. Concerning vitronectin 
expression in glioblastomas, other studies showed that most human astrocytic tumors 
are completely negative for vitronectin. Interestingly, only „loose focal vitronectin 
deposits“ were described in single cases of glioblastoma in one study (Zámecník et al., 
2003). This is quite in line with our findings, however we did not feel comfortable with the 
staining results and were not convinced that such „loose focal vitronectin deposits“ really 
represent specific staining signals. Furthermore, also the fact that vitronectin seems 
slightly downregulated in glioblastomas as compared to normal CNS tissue (see figure 
5) might be an additional indicator for our interpretation that the vitronectin staining 
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signals in glioblastomas are not reliable. In general, about half of the tumours expressed 
the other ligands, with a low frequency of expression of fibronectin and osteopontin in 
breast-derived metastases, and a higher expression of fibrinogen in lung-derived brain 
metastases. While a high expression of fibrinogen has been demonstrated in primary 
lung cancer tissue (Sierko et al., 2012), our data regarding low osteopontin expression in 
breast-derived brain metastases diverge from its reported high expression in primary 
breast carcinoma (Kim et al., 1998). The expression of integrin ligands did not clearly 
follow expression of individual integrins, despite vitronectin being described as a 
monospecific ligand for αvβ5, while fibrinogen and osteopontin preferentially target αvβ3 
(Hynes, 2002). Osteopontin has been described as increasing the migratory potential of 
cancer cells via activation of αvβ3 (Fong et al., 2009). The majority of tumours 
expressed osteopontin. The high levels of osteopontin expression in glioblastomas could 
be experimentally linked to an increased glioma cell invasion and proliferation (Jan et al., 
2010), correlate with the extent of angiogenesis in vivo (Matusan-Ilijas et al., 2008) and 
could meanwhile be established as a serum biomarker for worse patient prognosis in 
human gliomas (Sreekanthreddy et al., 2010). Concerning the expression of integrins 
and their corresponding integrin ligands in primary tumors or cells a similar 
heterogeneity similar to our study was described (Marshall et al., 1991; Taherian et al., 
2011). 
Overall, some tumours demonstrated high-frequency expression of integrins and 
their ligands. In addition, in glioblastomas, cDNA expression of αvβ3, αvβ5, osteopontin 
and fibronectin were significantly upregulated compared with normal CNS tissues. The 
role of αvβ3 and αvβ5 integrins in tumour development and metastasis is being 
exploited clinically. Cilengitide, a cyclised Arg-Gly-Asp (RGD)-containing peptide (Cyclo-
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[Asp-D-Phe-N-MeVal-Arg-Gly]), is a selective inhibitor of these integrins, and is currently 
being studied in the clinics in various tumours settings, including glioblastoma (Reardon 
et al., 2008; Stupp et al., 2010). Further studies are needed to reveal whether the 
expression of αvβ3 vs αvβ5 we have measured in brain tumours is related to hypoxia or 
ischaemia which can upregulate αvβ3 (but not αvβ5) (del Zoppo et al., 2006), or if this 
expression profile is a phenomenon intrinsic to the tumour itself.  
 
Michel Mittelbronn   15.7.12 13:02
Gelöscht:  relatively high
16 
 
Conclusions 
Integrins αvβ3 and αvβ5 in human glioblastoma and in CNS metastases from lung and 
breast cancer, and melanoma are expressed iin a distinct and heterogenous expression 
pattern. The differential expression of integrins and integrin ligands may help to develop 
targeted integrin-antagonistic therapies for human brain cancers. 
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Table 1. Antibodiesa, clones, and providers. 
Antibody Clone Provider 
Fibrinogen Polyclonal Dako Cytomation, 
Carpinteria, CA, USA 
Fibronectin Polyclonal Dako Cytomation, 
Carpinteria, CA, USA 
αvβ3 Lm609 (IgG1) Millipore, Schwalbach, 
Germany 
Osteopontin Polyclonal NeoMarkers, Lab Vision 
Corporation, CA, USA 
αvβ5 P1F6 (IgG1) Millipore, Schwalbach, 
Germany 
Vitronectin 153 Dr D. Seiffert, Scripps, La 
Jolla, CA, USA 
aRabbit polyclonal antibodies were used. IgG1, immunoglobulin 1. 
.
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Table 2. Numbers of frozen samples analysed (glioblastoma and central nervous 
system metastases of different origin). 
Antibody: αvβ3 αvβ5 Fibrinogen Fibronectin Osteopontin Vitronectin 
Glioblastoma 15 10 15 15 14 1 
Breast 15 10 10 10 9 14 
Lung 16 7 11 10 11 15 
Melanoma 16 9 9 11 11 14 
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Table 3. Data on expression of integrins and integrin ligands in stromal cells: numbers of 
tumours demonstrating minor/marked expression. 
Tumour origina: Breast Lung Melanoma 
αvβ3 9/6 3/6 2/4 
αvβ5 4/1 –b –b 
Vitronectin 2/8 0/10 0/6 
Fibronectin 2/6 0/7 0/3 
Osteopontin 6/1 5/1 1/1 
Fibrinogen 1/7 0/9c 1/3 
Each table entry shows the number of tumours with minor expression (expression 
frequency scores 0–3)/numbers of tumours with marked expression (expression 
frequency scores 4–5). χ2 analysis indicated no significant differences within the dataset. 
aTumours of central nervous system origin do not display stromal cells and this analysis 
was therefore not conducted for glioblastoma samples. bInsufficient number of samples 
for analysis. cAll samples had frequency score 5 (expression in >50% of cells). 
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Table 4. Data on expression of integrins and integrin ligands in tumor-associated blood 
vessels. 
Tumour origin: Glioblastoma Breast Lung Melanoma 
αvβ3 9/4/2 4/1/9 1/3/12 5/5/6 
αvβ5 5/4/0 6/2/2 3/4/0 3/6/0 
Vitronectin –a 2/1/10 0/1/12 0/3/11 
Fibronectin 0/0/15 0/2/8 1/1/8 3/1/7 
Osteopontin 0/4/10 0/4/5 1/3/4 1/3/4 
Fibrinogen 3/3/8 0/5/5 0/3/8 1/4/5 
Data shown refer to sections with blood vessel frequency score = 0 (no expression in 
blood vessels [lowest category])/blood vessel frequency score = 1 (moderate number of 
positive blood vessels/blood vessel frequency score = 3 (expression in most blood 
vessels). aInsufficient number of samples for analysis. 
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Figure legends 
Figure 1. Expression of αvβ3 and αvβ5 integrins in tumor cells of glioblastomas and 
central nervous system metastases from breast and lung cancer or melanoma.  
 
Figure 2. Immunhistochemical analysis of αvβ3 (a-d) and αvβ5 (e-f) integrins in 
glioblastomas (a, b and e, f) and central nervous system metastases from breast (c) and 
lung (g, h) cancer or melanoma (d) (original magnification 200x for all images; scale bar 
= 100µm). 
 
Figure 3. Expression of integrin ligands in tumor cells of glioblastomas and central 
nervous system metastases from breast and lung cancer or melanoma. FBG, fibrinogen; 
FTN, fibronectin; OPN, osteopontin; VTN, vitronectin. Vitronectin expression was not 
analysed in glioblastomas as only one sample was available. 
 
Figure 4. Immunhistochemical analysis of fibrinogen (a, b), fibronectin (c, d), 
osteopontin (e, f) and vitronectin (g, h) in glioblastomas (a, c, e) and central nervous 
system metastases from breast (d, h) and lung (b, f) cancer or melanoma (g) (original 
magnification 200x for all images; scale bar = 100µm). 
 
Figure 5. mRNA expression of integrins and their ligands in glioblastomas (n=424) 
relative to normal central nervous system tissues (n=11). The data derives from The 
Cancer Genome Atlas (TCGA) Data Portal (https://tcga-
data.nci.nih.gov/tcga/tcgaHome2.jsp). For this study, the TCGA Portal has been 
assessed in November 2011. Log2-fold mRNA expression changes are depicted.  
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